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Abstract
Background : Hepatitis C virus genotype 4 (HCV-4) is the most 
prevalent genotype in Central Africa. 
Aim : To compare epidemiology, clinical characteristics and any 
differences in access to HCV therapy in two populations of HCV-4 
patients residing in Belgium.
Methods : This multicenter study selected 473 HCV-4 patients 
from seven hospital databases and compared them according to 
ethnic origin, i.e., Black African (n = 331) or not (n = 142), for epi-
demiological, clinical, biological and histological characteristics. 
Interleukin 28B polymorphism (CC-genotype) was evaluated in a 
second cohort of 69 Black African and 30 non-Black African pa-
tients.
Results : Compared to other patients, the Black African patients 
were more likely to be female and were older, commonly over-
weight, frequently had abnormal glucose metabolism and arterial 
hypertension ; they were less likely to have dyslipidemia, a history 
of alcohol consumption or ALT elevation. The route of infection 
was more frequently unknown in Black African than in other pa-
tients. Black African patients had more HCV-4 subtypes, were less 
IUHTXHQWO\RI,/%&&JHQRW\SHDQGKDGOHVVVHYHUHOLYHUÀEURVLV
The proportion of patients who received antiviral treatment was 
similar in the two groups.
Conclusion : In this Belgian cohort, patients with HCV-4 infec-
tion were more frequently of Black African origin than of other 
origin. Infected Black African patients were more commonly 
 female, older at diagnosis, and had more co-morbidities than other 
SDWLHQWV WKH\DOVRKDG OHVVDGYDQFHG OLYHUÀEURVLV WKDQ LQIHFWHG
non-Black African patients and fewer had a CC genotype. (Acta 
gastro enterol. belg., 2015, 78, 365-372).
Key words : chronic hepatitis C, HCV, genotype 4, ethnicity, epidemi-
ology, antiviral treatment, DAA, metabolic factors.
Introduction 
Hepatitis C virus (HCV) is widely recognized as a 
global public health burden, causing severe complica-
tions, such as cirrhosis and hepatocellular carcinoma (1). 
Six HCV genotypes and numerous subtypes have been 
distinguished (1,2). Genotyping is of great importance in 
the management of HCV-infected patients as the geno-
type may affect the response to antiviral therapy and is 
crucial in understanding the epidemiological aspects of 
HCV infection, notably infection risk factors and geo-
graphic distribution (2-10). For example, HCV genotype 
4 (HCV-4) is highly prevalent in Egypt and the Middle 
East (80% of HCV infections in Egypt and over 30% in 
Syria) and Central Africa (100% in the Democratic Re-
public of Congo and Rwanda, 16 to 36% in Cameroon 
and 6.5% in Gabon) (3,9,11-15). As a result of popula-
tion migration and differing lifestyles, HCV-4 was pres-
ent in 1-3% of HCV-infected patients from Western 
countries during the 1990s. This prevalence is increasing 
in Europe (10,16-19). In Belgium, it increased from 4% 
for the period 1992-1994 to 12% in 2000-2002 (19). 
Most studies on HCV-4 epidemiology have been car-
ried out in Egypt and the Middle East. Because of the 
cost of diagnosing and genotyping HCV infection and 
the limited budget allocated to public health, large-scale 
trials to evaluate patient characteristics in sub-Saharan 
Africa are lacking, and infected patients in these coun-
tries are often untreated (in part due to under-diagnosis). 
However, it is possible to study the epidemiology of 
HCV-4-infected Black African (BA) patients who have 
immigrated to Europe. Therefore, the aim of this study 
was to compare the demographic characteristics of HCV-
4 infected BA and non-Black African (non-BA) patients 





gian hospitals (CHU Saint-Pierre, CHU Brugmann, 
Hôpital Universitaire Erasme, Hôpital Bracops and CH 
Molière, Brussels ; CHU Sart Tilman, Liège ; University 
Hospital, Antwerp), which are located in the three largest 
Belgian cities. Most patients were from Brussels.  Patients 
were eligible for the study if they were aged > 11 years 
and had HCV-4 infection diagnosed between 1999 and 
2007.
Since the effect of interleukin 28B (IL28B) polymor-
phism was unknown at the time of the original study, this 
characteristic was subsequently evaluated in two of the 
study centers (CHU Saint-Pierre, Hôpital Universitaire 
Erasme) in a second cohort of 99 consecutive, treatment-
naïve HCV-4 infected patients.
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performed using a Cobas Amplicor HCV monitor, ver-
sion 2.0 (Roche Systems) or an Amplicor HCV monitor, 
version 2.0. The HCV limit of detection in qualitative 
assays was 50 IU/mL. Genotyping was performed using 
assays from INNO-LIPA HCV II, Innogenetics, Ghent, 
Belgium or the Versant HCV genotyping assay, Bayer 
HealthCare.
Treatment regimens 
The criteria for starting antiviral therapy in Belgium 
followed international guidelines. To obtain antiviral 
treatment reimbursement in Belgium, social security ap-
proval must be obtained.
Statistical analysis
(SLGHPLRORJLFDOSURÀOHVZKHWKHURUQRWWKHUDS\ZDV
received, and reasons for not receiving treatment were 
recorded and compared in the two groups of patients
Baseline characteristics are presented as numbers of 
cases and percentages for categorical data, and as means 
with standard deviation (SD) or median and range for 
continuous data. 
Patient groups were compared using either Fisher’s 
exact test for binary categorical variables or chi-squared 
techniques for categorical variables with more than two 
OHYHOV$FUXGHRGGVUDWLR25ZLWKLWVFRQÀGHQFH
interval (CI) is presented for each comparison made. 
Continuous variables were compared using a  Student’s 
t test. The between-group differences are presented as the 
difference between the means of each group, with a 95% 
CI for each comparison made. To assess whether there 
was a difference in the degree of steatosis by BMI 
 between ethnic groups, the Cochran-Mantel-Haenszel 
statistic was used. To identify risk factors for bridging 
ÀEURVLVFLUUKRVLV25VDGMXVWHGIRUIDFWRUVZLWKDSYDOXH
 LQ FUXGH XQDGMXVWHG DQDO\VLV ZHUH FDOFXODWHG
baseline parameters used for this analysis included the 
following : age, sex, Black African versus other ethnici-
ty, mode of HCV infection, alcohol intake, BMI, HCV 
YLUHPLDDQGQHFURLQÁDPPDWRU\DFWLYLW\&RPSXWDWLRQDO
procedures were performed using SPSS for  Windows 
version 17.0 (SPSS Inc., Chicago, IL, USA).
$SYDOXHOHVVWKDQZDVFRQVLGHUHGVLJQLÀFDQW
Results
Epidemiological data for all patients 
In total, 473 patients (331 BA and 142 non-BA) with 
+&9ZHUHLGHQWLÀHG7DEOH
B A patients were from the Democratic Republic of 
Congo (n = 200), and Angola, Burundi, Cameroon, 
 Gabon or Rwanda (n = 131). Non-BA patients were 
 Caucasian Europeans from Belgium, France, Greece, 
 Italy, Portugal, Spain and Russia (n = 110) and North 
 Africans, mainly from Morocco but also from Algeria, 
Egypt and Tunisia (n = 32).
The study was conducted in conformity with the prin-
ciples of the Declaration of Helsinki and local laws and 
regulations. The institutional review boards of the par-
ticipating centers and the ethical committee of the main 
investigating center (CHU Saint-Pierre, Brussels, OM 
007) approved the study protocol.
Baseline parameters
Recorded baseline parameters included the follow-
LQJGHPRJUDSKLFVLQFOXGLQJHWKQLFRULJLQ%$GHÀQHG
as an individual whose parents were both from central 
Africa, Caucasian whites and North Africans), sex, age at 
diagnosis, body weight (kg), body mass index (BMI ; kg/
m2) and risk factors for infection.
Co-morbidities, including being overweight or obese 
(BMI > 25 or > 30 kg/m2, respectively), having dyslipid-
emia (on treatment, or above the upper limit of nor-
mal (ULN) for serum cholesterol and/or triglycerides), 
glucose metabolism impairment (including intolerance if 
fasting glycemia > 100 but < 125 mg/dL and overt diabe-
tes, treated or not), arterial hypertension (on treatment, or 
EORRGSUHVVXUH!PP+JUHQDOLQVXIÀFLHQF\LI
serum creatinine was over the ULN), alcohol consump-
WLRQ FODVVLÀHG DV QHYHU RFFDVLRQDOOHVV WKDQ  GULQNV
per month), active (equal to or above 3 drinks per month 
)or past intake (no drink in the year preceding inclu-
sion)), co-infection with hepatitis B virus (HBV) (pres-
HQFHRI+%V DQWLJHQ DQGRU KXPDQ LPPXQRGHÀFLHQF\
virus (HIV ; positive for antibodies and viremia) were 
UHFRUGHG 3UHYLRXV +%9 LQIHFWLRQ ZDV GHÀQHG DV WKH
presence of antibodies against the hepatitis B core anti-
gen. 
HCV-4 viral load was categorized as < 400,000 IU/mL 
or > 400,000 IU/mL, and viral subtypes were also stud-
ied.
The alanine aminotransferase (ALT) to ULN ratio was 
FODVVLÀHG DV  RU! RU SHUVLVWHQWO\ QRUPDO $/7
(NALT) over a 6- to-12-month period.
Liver biopsy specimens obtained before treatment 
were evaluated (locally and without blinding) using the 
0(7$9,5FODVVLÀFDWLRQIRUDFWLYLW\JUDGH$OLYHUÀ-
brosis stage (F) and degree of steatosis (20) . The follow-
ing groups were distinguished : METAVIR grade (A) < 2 
DQG 0(7$9,5 VWDJH ) DQG  'HJUHH RI
steatosis was based on the pathology report and graded as 
0 to < 10%, 10 to 30% and > 30% (21). 
With respect to IL28B genes, the frequency of the 
SNP rs12979860 CC-genotype was evaluated in a sub-
group of 99 patients as mentioned above.
Virology tests 
Quantitative tests measuring HCV RNA levels (ex-
pressed in IU/ml) were performed using a Cobas Ampli-
cor HCV monitor, version 2.0 (Roche Systems), a Ver-
sant HCV RNA 3.0 assay (Bayer HealthCare) or the 
Cobas Taqman HCV test (Roche Systems) and Abbott 
Real Time (Abbott Diagnostic). Qualitative tests were 
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were 9 folds, 5 folds, and 3 folds respectively more prev-
alent in BA patients than non-BA. 
The SNP rs12979860 CC-genotype was present in 
14/99 (14.1%) patients overall and in 6/69 (8.6%) BA 
compared with 8/30 (26.6%) non-BA patients (p = 0.01). 
Histological findings
7KHUHZDVQRVLJQLÀFDQWGLIIHUHQFHLQQHFURLQÁDPPD-
tory activity between the two groups (Table 3). Progres-
VLRQ RI OLYHU ÀEURVLV ZDV OHVV FRPPRQ LQ %$ WKDQ LQ
RWKHUSDWLHQWVS DVZDVEULGJLQJÀEURVLVFLUUKR-
sis (p = 0.03). 
6WHDWRVLV GLG QRW UHDFK D VLJQLÀFDQW GLIIHUHQFH EH-
WZHHQWKHWZRJURXSVEXWWKHGHJUHHRIVWHDWRVLVVWUDWLÀHG
E\%0,ZDVIRXQGVLJQLÀFDQWO\OHVVFRPPRQLQ%$SD-
tients (p = 0.02) (Table 4).
$JH HWKQLFLW\ DQG QHFURLQÁDPPDWRU\ DFWLYLW\ ZHUH
LGHQWLÀHGDVVWDWLVWLFDOO\VLJQLÀFDQWULVNIDFWRUVIRUEULGJ-
LQJÀEURVLVFLUUKRVLVLQXQLYDULDWHDQGPXOWLYDULDWHDQDO-
ysis (Table 5). 
Treatment and reason for non-treatment 
In this cohort, 273 patients received anti-viral therapy 
(Table 6). There was no difference in the proportion of 
treated patients in the BA and non-BA patients : 195/331 
Among the BA patients, 203 (61.3%) were female 
compared to 59 (41.5%) in the non-BA group (p < 0.001). 
%$SDWLHQWVZHUHVLJQLÀFDQWO\ROGHUWKDQRWKHUSDWLHQWVDW
WKHWLPHRIGLDJQRVLVSDQGWKHUHZHUHVLJQLÀ-
cant differences in risk factors for infection between the 
JURXSV S ,Q WKHPDMRULW\ RI %$ SDWLHQWV WKH
mode of transmission of HCV was unknown ; in other 
patients, intravenous drug use was the most commonly 
reported mode of transmission.
Clinical and biological characteristics 
%$ SDWLHQWV ZHUH VLJQLÀFDQWO\ KHDYLHU S 
than other patients and dyslipidemia was less common 
(p = 0.039). Glucose intolerance, overt diabetes and arte-
rial hypertension were more frequent in BA patients (all 
p =  < 0.01) (Table 2). The frequencies of HBV and/or 
HIV co-infection were similar in the two groups of pa-
WLHQWVDVZDVUHQDO LQVXIÀFLHQF\$OFRKROFRQVXPSWLRQ
was less common in BA than in other patients (p = 0.01). 
7KHUHZDVDVLJQLÀFDQWGLIIHUHQFHLQEDVHOLQH$/7OHYHOV
between groups (p < 0.001), with normal levels more 
common among BA patients. The median viral load was 
similar in the two groups. BA patients showed greater 
diversity with respect to viral subtypes than other pa-
tients (p < 0.001). Analysis of the predominant recog-
nized viral subtypes revealed that subtype 4e, 4a and 4h 
Table 1. — Baseline epidemiological data of the study cohort stratified according to ethnicity : Black African vs. other
Patient characteristics Black African* other * Odds ratio P-value ***
n 331 142 (95%CI) **
Male (%) 128/331 (38.7%) 83/142 (58.5%) 2.23 (1.50 to 3.33) < 0.001









6.7 (4.2 to 9.2) < 0.001
Patients older than 40 years (%) 233/320 (72.8%) 70/141 (49.6%) 2.72 (1.80 to 4.10) < 0.001
Infection risk factors
 Transfusion 70/330 (21.2%) 18/142 (12.6%)
 IVD user 9/330 (2.7%) 58/142 (40.8%) 0.012
 Unknown 215/330 (65.5%) 56/142 (39.4%)
 Other (sex, tattoo, intra-familial) 10/330 (3.0%) 8/142 (5.6%)









5.5 (2.2 to 8.7) 0.001
Co-morbidities










3.0 (1.9 to 4.1) < 0.001
– Alcohol Intake
 No intake 181/252 (71.8%) 56/103 (54.4%)
 Active intake 40/252 (15.9%) 30/103 (29.1%) 0.01
 Past intake 15/252 (6.0%) 10/103 (9.7%)
 Occasional intake 16/252 (6.3%) 7/103 (6.8%)
* In each group, data are presented as number of cases (percentages).
** CI : confidence interval.
*** P value comparing Black African (case) group versus other group. 
IVD : intravenous drug.
}
}
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Discussion 
In this large population of HCV-4 infected patients, 
epidemiological, clinical, biological, histological and 
treatment characteristics were analysed. 
Although less than 1% of the Belgian population (22) 
is of BA origin, 70% of patients in this observational 
study were BA, originating from central Africa. There-
fore we decided to compare patients of BA origin and 
those of other ethnic origin. 
These patients were more likely to be female than 
were the other patients, possibly due to more frequent 
(58.9%) and 78/142 (54.9%) respectively ; OR 1.16, 
95% CI (0.78 to 1.73), p = 0.46. The treatment prescribed 
for BA (n = 195) and non-BA (n = 78) patients included : 
interferon (IFN) alone (8 vs. 4), IFN plus ribavirin (RBV) 
(23 vs. 16), IFN plus RBV plus amantadine (AM) (4 vs. 
0), pegylated-IFN (peg-IFN) alone (1 vs. 1), peg-IFN 
plus RBV (128 vs. 48), peg-IFN plus RBV plus AM (31 
vs. 8) and peg-IFN plus AM (0 vs. 1).x
Two hundred patients (136 BA and 64 non-BA pa-
tients) did not receive treatment. There were no statisti-
FDOO\ VLJQLÀFDQWGLIIHUHQFHVEHWZHHQJURXSV LQ WKH UHD-
sons for lack of therapeutic intervention (Table 6).
Table 2. — Clinical and biological data of the study cohort stratified according to ethnicity : Black African vs. Other




– Dyslipidemia 55/250 (22.0%) 32/98 (32.7%) 0.59 (0.35 to 0.98) 0.03
– Glucose intolerance or diabetes (%) 77/274 (28.1%) 15/105 (14.3%) 2.35 (1.28 to 4.31) 0.007
– Arterial hypertension 103/266 (38.7%) 10/127 (7.8%) < 0.001
– Hepatitis B
 Active hepatitis B 24/289 (8.3%) 7/127 (5.5%) 0.10
 Past hepatitis B§ 82/289 (28.3%) 26/127 (20.5%)
 No hepatitis B 183/289 (63.3%) 94/127 (74.0%)
– HIV-positive (%) 38/319 (11.9%) 24/134 (17.9%) 0.62 (0.36 to 1.09) 0.12
– Abnormal renal function 45/271 (16.6%) 16/104 (15.4%) 1.10 (0.59 to 2.04) 0.77
HCV viral load (x103 IU/ml)
 Median
 1st-3 rd 
 (n = 257)
 798.9
 343 to 1492
 (n = 115)
 850.0
 304 to 1838
0.35
Patients with viral load 
> 400× 103 IU/ml (%)
187/257 (72.8%) 82/115 (71.3%) 1.08 (0.66 to 1.75) 0.77
Subtype
 unrecognized subtype 4 198/326 (60.7%) 57/136 (41.9%)
 subtype 4a 17/326 (5.2%) 1/136 (0.7%)
 subtype 4b 1/326 (0.3%) 1/136 (0.7%)
 subtype 4c 3/326 (0.9%) 0/136 (0%)
 subtype 4c/4d 44/326 (13.4%) 67/136 (49.2%)
 subtype 4d 0/326 (0%) 1/136 (0.7%)
 subtype 4e 39/326 (11.9%) 4/136 (2.9%) < 0.001
 subtype 4h 19/326 (5.8%) 4/136 (2.9%)
 VXEW\SHDƋ 1/326 (0.3%) 0/136 (0%)
 VXEW\SHDƋƋ 1/326 (0.3%) 0/136 (0%)
 subtype 4k 2/326 (0.6%) 0/136 (0%)
 VXEW\SHHƋ 1/326 (0.3%) 1/136 (0.7%)
Transaminase ALT
 Normal 84/303 (27.7%) 20/133 (15.0%)
 < 2 ULN 159/303 (52.4%) 63/133 (47.4%) < 0.001
 > 2 ULN 60/303 (19.8%) 50/133 (37.6%)
IL28B polymorphism
  CC-genotype 6/69 (8.7%) 8/30 (26.6%) 3.82 (1.19-12.39) 0.01
* In each group, data are presented as number of cases (percentages).
** 95% CI, 95% confidence interval.
*** P value comparing Black African (case) group versus other group.
§P-value= 0.09.
1st -3rd, first - third quintiles.
ƋDQGƋƋPL[WXUHZLWK+&9JHQRW\SHDDQGEUHVSHFWLYHO\
ULN upper limit of normal.
}
}
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In Africa, blood transfusion has been an important risk 
factor for HCV infection for longer than in Europe, and 
was found to be a key risk factor in both younger and 
older BA patients. Other potential iatrogenic risk factors 
for HCV transmission in the BA population include in-
tramuscular treatment for sexually transmitted infections 
or for malaria, dental procedures, and needle-stick acci-
dents. Non-iatrogenic routes of HCV-infection in central 
$IULFD LQFOXGHWUDGLWLRQDOSUDFWLFHVVFDULÀFDWLRQSLHUF-
ing), circumcision/excision, razor sharing at barbers’ 
shops, toothbrush sharing, and sexual contact (3,9). 
HCV-4 subtypes are more diverse in BA patients than 
in patients of other ethnic origin, possibly because, his-
torically, this genotype was well established in central 
Africa before spreading to other regions (2,3,5). For ex-
ample, considering the recognized subtypes, subtypes 4e, 
4a, and 4h were highly prevalent in the BA population in 
comparison to non-BA patients. In Europe, HCV-4 ap-
peared only recently as a result of immigration and has 
been propagated by intravenous drug abuse and sexual 
behavior such as anal intercourse (3,7-8,11). Subtypes 
4c/4d, the subtypes most frequently found in intravenous 
GUXJXVHUVZHUHVLJQLÀFDQWO\PRUHFRPPRQLQWKHQRQ
BA group (11). 
HCV screening in women (i.e. antenatal testing), al-
WKRXJKWKLVFRXOGDOVRUHÁHFWWKHGHPRJUDSK\RIWKHVXE
Saharan African population in Belgium at the time when 
the study was carried out (22,23).
Overall, the BA patients in our study were older than 
the non-BA patients and HCV-4 infection was diagnosed 
later in life (Table 1). Age and duration of infection are 
IDFWRUVSUHGLFWLYHRIÀEURVLVDQGUHVSRQVHWRWKHUDS\LQ-
cluding pegIFN and ribavirin (4,24,25). 
Differences in risk factors for transmission of HCV 
between patients of different ethnic origin may result 
IURPKLVWRULFDOFXOWXUDODQGÀQDQFLDOGLIIHUHQFHV
9). Older BA patients with no known risk factors for in-
fection could have been infected during mass treatment 
campaigns against Trypanosomiasis (in the Democratic 
Republic of Congo, Gabon, and Cameroon), or during 
mass vaccination campaigns carried out in central Africa 
during the last century ; in both cases reuse of medical 
instruments without adequate sterilization has been de-
scribed. Patients originating from North Africa could 
also have been exposed to this risk factor ; notably, in 
Egypt, HCV-4 was spread during mass treatment cam-
paigns against Schistosomiasis, resulting in a high preva-




Table 3. — Liver histology of patients stratified according to the ethnicity : Black African vs. Other





A-0 29 (12.7%) 10 (11.2%)
A-1 118 (51.8%) 57 (64.0%)
A-2 73 (32.0%) 17 (19.1%) 0.98
A-3 8 (3.5%) 5 (5.6%)





F-0 46 (18.6%) 18 (16.2%)
0.04F-1 85 (34.4%) 41 (36.9%)F-2 71 (28.7%) 21 (18.9%)
F-3 20 (8.1%) 20 (18.0%)
F-4 25 (10.1%) 11 (9.9%)





S-0 or < 10% 141 (81.0%) 56 (70.8%)     
S-10-30% 26 (14.9%) 15 (18.9%)             0.09
S- > 30% 7 (4.0%) 8 (10.1%)
Table 4. — Relationship between steatosis and body mass index stratified according to the ethnicity :  
Black African vs. Other









Steatosis < 10% 42 (93%) 84 (73.6%) 27 (69.2%) 21 (65.6%)
Steatosis ³ 10% 3 (6.6%) 25 (21.9%) 12 (30.7%) 11 (34.3%)
*P  =  0.02.
BMI  Body  Mass  Index  (kg/m2) ; Among 174 Black African and 79 other patients who had the steatosis evaluation, BMI data were unavailable in 
15 (8.6%) Black African and in 6 (7.5%) non-Black African patients.
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HCV may be more common than co-infection. The 
 frequency of HCV-4/HIV co-infection we observed is 
consistent with reports from other studies (14,30).
Normal transaminase values were seen more com-
monly among BA patients in our study. In studies from 
WKH86 D WUHQG WRZDUGVQRUPDO RU ORZHU$/7SURÀOHV
was seen among African-American patients, with normal 
ALT levels observed to be more common among females 
with a long history of HCV infection (31,32). It has been 
HVWDEOLVKHG WKDW WKHGLVWULEXWLRQRI$/7 OHYHOV LV LQÁX-
enced by factors such as duration of infection, ethnicity 
(lower levels in black African patients), sex (lower levels 
in women), obesity and geographic region (33-37). 
Studies on chronic hepatitis C from the US have often 
VKRZQDVORZHUSURJUHVVLRQRIÀEURVLVDQGDQLQIUHTXHQW
cirrhosis’ state in African-American patients (31,32). In 
the present study, despite more frequent co-morbidities, 
%$SDWLHQWVZHUHDOVROHVVOLNHO\WRKDYHEULGJLQJÀEUR-
sis/cirrhosis than other patients. Moreover, in multi-
variate analysis, ethnicity appeared to be a strong predic-
WRURIEULGJLQJÀEURVLVFLUUKRVLV2QHRIWKHUHDVRQVIRU
WKH VORZHU SURJUHVVLRQ RI ÀEURVLV DPRQJ $IULFDQ
American patients relates to dysfunctional lymphocyte T 
CD4 responsiveness to HCV (38) ; this could also apply 
Co-morbidities (excess weight, glucose metabolism 
impairment and arterial hypertension) were markedly 
more common among BA patients. However, despite be-
ing more frequently overweight, fewer BA patients had 
dyslipidemia, suggesting weight gain from a diet high in 
carbohydrates rather than in saturated fats. These co-
morbidities (excess weight, glucose metabolism impair-
ment, arterial hypertension, and dyslipidemia) are com-
ponents of the metabolic syndrome, which has previously 
been shown to be prevalent in BA individuals (26). 
 Moucari et al. found that metabolic syndrome and geno-
types 1 and 4 were associated with insulin-resistance in 
non-diabetic patients with chronic hepatitis C (27). De-
spite this higher prevalence of metabolic syndrome, BA 
 patients with HCV-4 infection in our study had a lower 
IUHTXHQF\RIOLYHUVWHDWRVLVZKHQVWUDWLÀHGE\%0,WKLV
observation has also been made among African- American 
patients (often infected with HCV genotype 1) (28,29). 
7KHUHLVSRVVLEO\DJHQHWLFH[SODQDWLRQIRUWKLVÀQGLQJ
which may also be relevant to those of BA origin. 
We found a slightly higher frequency of HCV-4-HBV 
co-infection than reported in one French study (8). In 
 regions of HBV endemicity, such as Africa, infection 
 frequently occurs early in life ; hence superinfection with 
Table 5. — Risk factors for bridging fibrosis/cirrhosis
Unadjusted Adjusted
Parameters METAVIR fibrosis stage 
3 or 4




Age 0.01 0.30 (0.12-0.77) 0.01
 > 40 (n = 195) 





Ethnicity 0.03 0.44 (0.21-0.96) 0.04
    Black African (n = 247) 202 (81.7%) 45 (18.2%)
    non-Black African (n = 112) 80 (71.4%) 32 (28.5%)
Sex 0.09 1.0 (0.53-2.03) 0.9
    female (n = 195) 160 (82.0%) 35 (17.9%)
    male (n = 164) 122 (74.3%) 42 (25.6%)
Alcohol
abstainer (n = 196 ) 
others (n = 61)
Risk factor
unknown (n = 200)
others (n = 159)
Body mass index
    > 25 (n = 172)
    < 25 (n = 106)
HCV viremia*
    > 800000    (n = 162)































No (n = 213)





OR odds ratio, *IU/ml.
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Conclusion
7KHPDMRULW\RI+&9LQIHFWHGSDWLHQWVLQ%HOJLXP
were found to be of Black African origin. Although 
Black African patients showed less evidence of advanced 
liver disease, they were older, had more co-morbidities, 
and were less frequently of IL28B CC-genotype than 
non-Black African patients. 
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